Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced NSCLC.

Detailed Description
-----------------
By enrolling patients with NSCLC adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and nature killer (NK) cells for NSCLC. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Conditions
-----------------
Non-small Cell Lung Cancer Metastatic

Intervention / Treatment
-----------------
* Device: Cryosurgery
* Biological: NK Immunotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence Body tumor 1-6, the maximum tumor length < 5 cm KPS ≥ 70, lifespan > 6 months Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L Exclusion Criteria: Patients with cardiac pacemaker Patients with brain metastasis Patients withgrade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cryosurgery and NK immunotherapy<br>In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell). | Device: Cryosurgery<br>* Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)<br>Biological: NK Immunotherapy<br>* Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)<br>|
| Active Comparator: Cryosurgery<br>In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell). | Device: Cryosurgery<br>* Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relief degree | It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST） | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progress free survival（PFS） |  | 1 year | 
| Overall survival（OS） |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-small cell lung cancer, Cryosurgery, NK Immunotherapy